Immuron (Immuron) Common Stock : $59.19 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Immuron Common Stock?

Immuron's quarterly common stock declined from Dec. 2022 ($59.67 Mil) to Jun. 2023 ($59.35 Mil) and declined from Jun. 2023 ($59.35 Mil) to Dec. 2023 ($59.19 Mil).

Immuron's annual common stock declined from Jun. 2021 ($67.55 Mil) to Jun. 2022 ($62.15 Mil) and declined from Jun. 2022 ($62.15 Mil) to Jun. 2023 ($59.35 Mil).

Immuron Common Stock Historical Data

The historical data trend for Immuron's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Common Stock Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Common Stock

Get a 7-Day Free Trial

41.87

43.08

67.55

62.15

59.35

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial												63.26	62.15	59.67	59.35	59.19

Immuron Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Immuron (Immuron) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (NAS:IMRN) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

ANWA:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.